Achilles Therapeutics (ACHL)
Achilles Therapeutics Statistics
Share Statistics
Achilles Therapeutics has 41.1M shares outstanding. The number of shares has increased by 0.03% in one year.
| Shares Outstanding | 41.1M |
| Shares Change (YoY) | 0.03% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 60.1% |
| Shares Floating | 20.06M |
| Failed to Deliver (FTD) Shares | 5.47K |
| FTD / Avg. Volume | 0.43% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.51 and the forward PE ratio is null. Achilles Therapeutics's PEG ratio is 0.12.
| PE Ratio | -0.51 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.25 |
| P/FCF Ratio | -0.72 |
| PEG Ratio | 0.12 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Achilles Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.57, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.57 |
| Quick Ratio | 8.57 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.07 |
| Debt / FCF | -0.09 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-341.5K |
| Employee Count | 204 |
| Asset Turnover | 0 |
| Inventory Turnover | 4.73M |
Taxes
| Income Tax | 491K |
| Effective Tax Rate | -0.71% |
Stock Price Statistics
The stock price has increased by 88.82% in the last 52 weeks. The beta is 1.25, so Achilles Therapeutics's price volatility has been higher than the market average.
| Beta | 1.25 |
| 52-Week Price Change | 88.82% |
| 50-Day Moving Average | 1.32 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 76.37 |
| Average Volume (20 Days) | 1.28M |
Income Statement
| Revenue | n/a |
| Gross Profit | -4.73M |
| Operating Income | -75.25M |
| Net Income | -69.67M |
| EBITDA | -70.44M |
| EBIT | -75.16M |
| Earnings Per Share (EPS) | -1.74 |
Balance Sheet
The company has 131.54M in cash and 4.62M in debt, giving a net cash position of 126.92M.
| Cash & Cash Equivalents | 131.54M |
| Total Debt | 4.62M |
| Net Cash | 126.92M |
| Retained Earnings | -259.95M |
| Total Assets | 122.68M |
| Working Capital | 93.16M |
Cash Flow
In the last 12 months, operating cash flow was -48.45M and capital expenditures -1.1M, giving a free cash flow of -49.55M.
| Operating Cash Flow | -48.45M |
| Capital Expenditures | -1.1M |
| Free Cash Flow | -49.55M |
| FCF Per Share | -1.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACHL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ACHL is $4, which is 170.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $4 |
| Price Target Difference | 170.3% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -2.67 |
| Piotroski F-Score | 1 |